Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

BioCorRx (BICX) Amortization of Deferred Charges (2016 - 2025)

BioCorRx (BICX) has disclosed Amortization of Deferred Charges for 5 consecutive years, with $1877.0 as the latest value for Q4 2025.

Quarterly Amortization of Deferred Charges fell 98.15% to $1877.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $103602.0 through Dec 2025, up 1.85% year-over-year, with the annual reading at $55738.0 for FY2025, 91.03% down from the prior year.
Amortization of Deferred Charges hit $1877.0 in Q4 2025 for BioCorRx, down from $101725.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $101725.0 in Q4 2024 to a low of $1877.0 in Q4 2025.